35 analyst firms have reported ratings in the last year. The last upgrade for Quest Diagnostics Inc happened on January 6, 2025 when Leerink Partners raised their price target to $174. Leerink ...

Diving into Analyst Ratings: An In-Depth Exploration The analysis of recent analyst actions sheds light on the perception of Quest Diagnostics by financial experts. The following summary presents ...

and adjustments to ratings and price targets. Capture valuable insights into Quest Diagnostics's market standing by understanding these analyst evaluations alongside pertinent financial indicators.

Moreover, Quest Diagnostics has increased its quarterly dividend by 6.7%, to $0.80 per share. In terms of analyst outlook, Jefferies has maintained their Buy rating for Quest Diagnostics and ...

Truist Financial analyst David S Macdonald maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today. The company’s shares closed yesterday at $172.84. Discover outperforming ...

On Monday, Leerink Partners analyst Michael Cherny upgraded shares of Quest Diagnostics (NYSE:DGX) stock from Market Perform to Outperform, increasing the price target from $169 to $174.

On Monday, Baird made a slight adjustment to the stock price target of Quest Diagnostics (NYSE:DGX), reducing it to $181 from $182, while reiterating an Outperform rating on the company's stock.

Therefore, the Zacks rating upgrade for Quest Diagnostics basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Decoding Analyst Ratings: A Detailed Look A comprehensive examination of how financial experts perceive Quest Diagnostics is derived from recent analyst actions. The following is a detailed ...

Mizuho lifts Quest Diagnostics target to $178 on strong outlook ...